FI113865B - Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa - Google Patents
Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossaInfo
- Publication number
- FI113865B FI113865B FI961696A FI961696A FI113865B FI 113865 B FI113865 B FI 113865B FI 961696 A FI961696 A FI 961696A FI 961696 A FI961696 A FI 961696A FI 113865 B FI113865 B FI 113865B
- Authority
- FI
- Finland
- Prior art keywords
- phenyl
- quinoline
- deriv
- tetrahydropyridazino
- aryl
- Prior art date
Links
- 201000006474 Brain Ischemia Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000005605 benzo group Chemical group 0.000 abstract 2
- 125000002541 furyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 1
- 241000689227 Cora <basidiomycete fungus> Species 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 1
- OHZYAOYVLLHTGW-UHFFFAOYSA-N pyrido[3,2-c]pyridazine Chemical class C1=CN=NC2=CC=CN=C21 OHZYAOYVLLHTGW-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI970907A FI114916B (fi) | 1993-10-22 | 1997-03-03 | Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino- [4,5-b]kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939321854A GB9321854D0 (en) | 1993-10-22 | 1993-10-22 | Pyridazino quinoline compounds |
| GB9417171A GB9417171D0 (en) | 1994-08-25 | 1994-08-25 | Pyridazino quinoline compounds |
| PCT/GB1994/002295 WO1995011244A1 (en) | 1993-10-22 | 1994-10-20 | Pyridazino quinoline compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI961696A0 FI961696A0 (fi) | 1996-04-18 |
| FI961696L FI961696L (fi) | 1996-04-18 |
| FI113865B true FI113865B (fi) | 2004-06-30 |
Family
ID=26303731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI961696A FI113865B (fi) | 1993-10-22 | 1996-04-18 | Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa |
| FI970907A FI114916B (fi) | 1993-10-22 | 1997-03-03 | Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino- [4,5-b]kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI970907A FI114916B (fi) | 1993-10-22 | 1997-03-03 | Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino- [4,5-b]kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US5744471A (cs) |
| EP (2) | EP0724583B1 (cs) |
| JP (1) | JP3583132B2 (cs) |
| KR (1) | KR100261209B1 (cs) |
| CN (1) | CN1053189C (cs) |
| AT (2) | ATE198072T1 (cs) |
| AU (2) | AU688393B2 (cs) |
| CA (1) | CA2171332A1 (cs) |
| CZ (1) | CZ292311B6 (cs) |
| DE (2) | DE69434380T2 (cs) |
| DK (2) | DK0724583T3 (cs) |
| ES (2) | ES2154686T3 (cs) |
| FI (2) | FI113865B (cs) |
| GB (1) | GB9420590D0 (cs) |
| GR (1) | GR3035080T3 (cs) |
| HU (1) | HUT74161A (cs) |
| IL (1) | IL111266A (cs) |
| MY (2) | MY132875A (cs) |
| NO (1) | NO306995B1 (cs) |
| NZ (2) | NZ329303A (cs) |
| PL (1) | PL180679B1 (cs) |
| PT (2) | PT724583E (cs) |
| RU (1) | RU2168511C2 (cs) |
| SG (2) | SG59971A1 (cs) |
| SI (2) | SI0724583T1 (cs) |
| SK (1) | SK282491B6 (cs) |
| TW (1) | TW406082B (cs) |
| UA (1) | UA60291C2 (cs) |
| WO (1) | WO1995011244A1 (cs) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9420590D0 (en) * | 1993-10-22 | 1994-11-30 | Zeneca Ltd | Pyridazino quinoline compounds |
| GB9422894D0 (en) * | 1994-11-12 | 1995-01-04 | Zeneca Ltd | Pyridazino quinoline compounds |
| US6214826B1 (en) | 1994-11-12 | 2001-04-10 | Zeneca Limited | Pyridazino quinoline compounds |
| GB9507318D0 (en) * | 1995-04-07 | 1995-05-31 | Zeneca Ltd | Alpha substituted pyridazino quinoline compounds |
| EP1244662B1 (en) * | 1999-12-23 | 2005-04-27 | AstraZeneca AB | Pyridazino quinoline derivative and method for the treatment of pain |
| EP1577311A1 (en) * | 1999-12-23 | 2005-09-21 | AstraZeneca AB | Salts of a pyridazino aquinoline derivative and use for the treatment of pain |
| US6730675B2 (en) | 1999-12-23 | 2004-05-04 | Astrazeneca Ab | Compounds and methods for the treatment of pain |
| US20030176435A1 (en) * | 2002-12-17 | 2003-09-18 | Brown Dean Gordon | Compounds and methods for the treatment of pain |
| DE60013326T2 (de) * | 1999-12-23 | 2005-09-08 | Astrazeneca Ab | Verbindungen und verfahren zur behandlung von schmerz |
| WO2001047926A1 (en) * | 1999-12-23 | 2001-07-05 | Astrazeneca Ab | Compounds and methods for the treatment of pain |
| WO2001047924A1 (en) * | 1999-12-23 | 2001-07-05 | Astrazeneca Ab | Methods and compositions for the treatment of pain |
| US6943165B2 (en) * | 1999-12-23 | 2005-09-13 | Astrazeneca Ab | Compound and method for the treatment of pain |
| JP2003519147A (ja) * | 1999-12-23 | 2003-06-17 | アストラゼネカ・アクチエボラーグ | 痛みの処置のための化合物および方法 |
| US6787547B2 (en) | 1999-12-23 | 2004-09-07 | Astrazeneca Ab | Compound and method for the treatment of pain |
| HK1048767A1 (zh) * | 1999-12-23 | 2003-04-17 | 阿斯特拉曾尼卡有限公司 | 治疗疼痛的方法和组合物 |
| JP2003518500A (ja) * | 1999-12-23 | 2003-06-10 | アストラゼネカ・アクチエボラーグ | 痛みの処置のための方法および組成物 |
| US6403818B1 (en) | 2000-02-28 | 2002-06-11 | Eisai Co., Ltd. | Process for producing α-hydroxy-carbonyl compound |
| DE60121978D1 (de) | 2000-09-29 | 2006-09-14 | Astrazeneca Ab | 7-CHLOR-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON SCHMERZEN |
| US20050070544A1 (en) * | 2000-09-29 | 2005-03-31 | Astrazeneca Ab | 1,2,5,10-tetrahydropyridazino{4,5-b}quinoline-1,10-diones and their use for the treatment of pain |
| ES2263661T3 (es) | 2000-09-29 | 2006-12-16 | Astrazeneca Ab | 1,2,5,10-tetrahidropiridazino(4,5-b)quinolin-1,10-dionas y su uso para el tratamiento del dolor. |
| EP1325004A1 (en) * | 2000-09-29 | 2003-07-09 | AstraZeneca AB | 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| EP1390349B1 (en) * | 2001-05-31 | 2012-07-25 | Sanofi | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| EP1655301B1 (en) * | 2003-08-04 | 2015-03-11 | Valery Khazhmuratovich Zhilov | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
| US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| ES2656017T3 (es) | 2004-06-24 | 2018-02-22 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
| JP2009521468A (ja) * | 2005-12-24 | 2009-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｂｃ輸送体の調節因子としてのキノリン−４−オン誘導体 |
| EP1993360B1 (en) | 2005-12-28 | 2017-02-08 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| SI3330255T1 (sl) | 2009-03-20 | 2021-03-31 | Vertex Pharmaceuticals Incorporated | Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| NZ629199A (en) | 2012-02-27 | 2017-01-27 | Vertex Pharma | Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| WO2016057730A1 (en) | 2014-10-07 | 2016-04-14 | Strohmeier Mark | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8814458D0 (en) * | 1988-06-17 | 1988-07-20 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| GB9208511D0 (en) * | 1991-05-09 | 1992-06-03 | Ici Plc | Compounds |
| GB9109972D0 (en) * | 1991-05-09 | 1991-07-03 | Ici Plc | Therapeutic compounds |
| GB9420590D0 (en) * | 1993-10-22 | 1994-11-30 | Zeneca Ltd | Pyridazino quinoline compounds |
| GB9422894D0 (en) * | 1994-11-12 | 1995-01-04 | Zeneca Ltd | Pyridazino quinoline compounds |
| GB9507318D0 (en) * | 1995-04-07 | 1995-05-31 | Zeneca Ltd | Alpha substituted pyridazino quinoline compounds |
-
1994
- 1994-10-12 GB GB9420590A patent/GB9420590D0/en active Pending
- 1994-10-12 IL IL11126694A patent/IL111266A/xx not_active IP Right Cessation
- 1994-10-20 KR KR1019960702011A patent/KR100261209B1/ko not_active Expired - Fee Related
- 1994-10-20 SG SG1996007261A patent/SG59971A1/en unknown
- 1994-10-20 SI SI9430314T patent/SI0724583T1/xx unknown
- 1994-10-20 MY MYPI98002508A patent/MY132875A/en unknown
- 1994-10-20 DE DE69434380T patent/DE69434380T2/de not_active Expired - Fee Related
- 1994-10-20 SG SG9900943A patent/SG92630A1/en unknown
- 1994-10-20 DK DK94930275T patent/DK0724583T3/da active
- 1994-10-20 RU RU96109470/04A patent/RU2168511C2/ru not_active IP Right Cessation
- 1994-10-20 US US08/637,641 patent/US5744471A/en not_active Expired - Fee Related
- 1994-10-20 DE DE69426422T patent/DE69426422T2/de not_active Expired - Fee Related
- 1994-10-20 WO PCT/GB1994/002295 patent/WO1995011244A1/en active IP Right Grant
- 1994-10-20 ES ES94930275T patent/ES2154686T3/es not_active Expired - Lifetime
- 1994-10-20 CZ CZ19961138A patent/CZ292311B6/cs not_active IP Right Cessation
- 1994-10-20 MY MYPI94002796A patent/MY124316A/en unknown
- 1994-10-20 UA UA96041567A patent/UA60291C2/uk unknown
- 1994-10-20 HU HU9600889A patent/HUT74161A/hu unknown
- 1994-10-20 DK DK00101917T patent/DK1004582T3/da active
- 1994-10-20 CA CA002171332A patent/CA2171332A1/en not_active Abandoned
- 1994-10-20 ES ES00101917T patent/ES2241513T3/es not_active Expired - Lifetime
- 1994-10-20 AT AT94930275T patent/ATE198072T1/de not_active IP Right Cessation
- 1994-10-20 JP JP51152195A patent/JP3583132B2/ja not_active Expired - Fee Related
- 1994-10-20 AT AT00101917T patent/ATE295846T1/de not_active IP Right Cessation
- 1994-10-20 NZ NZ329303A patent/NZ329303A/xx not_active IP Right Cessation
- 1994-10-20 EP EP94930275A patent/EP0724583B1/en not_active Expired - Lifetime
- 1994-10-20 CN CN94194578A patent/CN1053189C/zh not_active Expired - Fee Related
- 1994-10-20 PT PT94930275T patent/PT724583E/pt unknown
- 1994-10-20 SI SI9430476T patent/SI1004582T1/xx unknown
- 1994-10-20 EP EP00101917A patent/EP1004582B1/en not_active Expired - Lifetime
- 1994-10-20 NZ NZ275472A patent/NZ275472A/en not_active IP Right Cessation
- 1994-10-20 PT PT00101917T patent/PT1004582E/pt unknown
- 1994-10-20 SK SK504-96A patent/SK282491B6/sk not_active IP Right Cessation
- 1994-10-20 AU AU79440/94A patent/AU688393B2/en not_active Ceased
- 1994-10-20 PL PL94314041A patent/PL180679B1/pl not_active IP Right Cessation
- 1994-11-18 TW TW083110721A patent/TW406082B/zh not_active IP Right Cessation
-
1996
- 1996-04-18 FI FI961696A patent/FI113865B/fi active
- 1996-04-19 NO NO961584A patent/NO306995B1/no not_active IP Right Cessation
-
1997
- 1997-03-03 FI FI970907A patent/FI114916B/fi active IP Right Grant
-
1998
- 1998-03-19 US US09/044,109 patent/US6232313B1/en not_active Expired - Fee Related
- 1998-05-27 AU AU68999/98A patent/AU721139B2/en not_active Ceased
-
1999
- 1999-12-06 US US09/455,096 patent/US6103721A/en not_active Expired - Fee Related
-
2000
- 2000-12-14 GR GR20000402690T patent/GR3035080T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI113865B (fi) | Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa | |
| BR9707495A (pt) | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente | |
| EA199901014A1 (ru) | C-4"-замещенные макролидные производные | |
| DE69232854D1 (de) | Bizyklische fibrinogenantagonisten | |
| KR920701165A (ko) | 골수세포형성 촉진에 유용한 헤테로아릴-3-옥소-프로판니트릴 유도체 | |
| DE60216610D1 (de) | Verwendung von kondensierten Pyrazolverbindungen für die Herstellung eines Arzneimittels zur Behandlung von Bluthochdruck | |
| FI104071B (fi) | Analogiamenetelmä terapeuttisesti käyttökelpoisten 2,5-dihydro-2,5-diokso-1H-bents£b|atsepiinijohdannaisten valmistamiseksi | |
| ATE404558T1 (de) | Antimikrobielle 4-oxochinolizinverbindungen, die als teilstruktur ein 2-pyridonskelett aufweisen | |
| GR3021344T3 (en) | Benzimidazole anthelmintic agents. |